Entries by

Abstract Accepted to ASCO 2021: Discovery of a potential predictive marker for eribulin treatment and novel target genes in BRAF V600E mutant metastatic colorectal cancer using an AI-driven RNA-seq analysis platform: Translational research of the BRAVERY study (EPOC1701)

Ocean Genomics leveraged its AI-driven transcriptome analysis and biomarker discovery platform, to identify a potential predictive RNA-seq driven biomarker in BRAF V600E mt mCRC.